PFG
VRTX icon

PAX Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

PAX Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-652
Closed -$316K – 273
2025
Q1 		$316K Buy
+652
New +$304K 0.06% 204
2020
Q4 		– Sell
-1,258
Closed -$342K – 148
2020
Q3 		$342K Buy
1,258
+247
+24% +$68.1K 0.12% 116
2020
Q2 		$294K Buy
1,011
+221
+28% +$59.9K 0.11% 117
2020
Q1 		$213K Buy
+790
New +$181K 0.09% 106

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PAX Financial Group's VRTX Position: Q2 2025 in Review

PAX Financial Group sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 652 shares — an estimated $316K sold.

PAX Financial Group first reported a position in VRTX in Q1 2020 and held it in 4 quarters. The position peaked at $342K in Q3 2020. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • PAX Financial Group reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • PAX Financial Group sold 652 Vertex Pharmaceuticals shares in Q2 2025, an estimated $316K.
  • PAX Financial Group first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 4 quarters.
  • PAX Financial Group's Vertex Pharmaceuticals position peaked at $342K in Q3 2020.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on PAX Financial Group's 13F filing for Q2 2025, filed 11 Aug 2025.